Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27829788 | 0.78 | AKR1C3 (0.83) | AKR1C3NPSR1LMNATSHRALDH1A1 | |
| SCHEMBL24937757 | 0.75 | AKR1C3 (0.66) | AKR1C3NPSR1LMNATSHRALDH1A1 | |
| SCHEMBL21657708 | 0.74 | AKR1C3 (0.64) | AKR1C3NPSR1LMNAMAPTTSHR | |
| SCHEMBL5457650 | 0.73 | DRD2 (0.77) | AKR1C3NPSR1LMNATSHRALDH1A1 | |
| SCHEMBL19078785 | 0.73 | AKR1C3 (0.59) | AKR1C3LMNAMAPTTSHRALDH1A1 | |
| SCHEMBL16026545 | 0.73 | PKM (0.74) | AKR1C3NPSR1LMNATSHRALDH1A1 | |
| SCHEMBL31199173 | 0.72 | LMNA (0.57) | LMNAMAPTTSHRALDH1A1POLB | |
| SCHEMBL3904994 | 0.71 | KMT2A (0.68) | AKR1C3NPSR1LMNATSHRALDH1A1 | |
| SCHEMBL7793932 | 0.71 | AKR1C3 (0.68) | AKR1C3NPSR1LMNATSHRALDH1A1 | |
| SCHEMBL10062332 | 0.71 | KMT2A (0.61) | NPSR1LMNATP53MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | SOLEY THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20240374589-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | MKI67, BCL2, CCAR2 | AKR1C3 2947/4885NPSR1 3651/4885LMNA 2935/4885 |
| US-20240374589-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | MKI67, HDAC6, BCL2 | AKR1C3 2691/4885NPSR1 3470/4885LMNA 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.